Lentivirus GMP Production
As the number and variety of planned CAR-T and gene therapy trials increases with each year, the need for GMP lentivirus also continues to grow. At Vigene, we are passionate about our mission to help support scientists advance their biomedical research and, ultimately, to make gene therapy affordable and accessible to those in need.
As a leader in GMP lentivirus production, we have the experience and dedication to quality that you need to scale up your lentivirus gene therapy project into a patient-ready product. We know that there is no single production strategy that works best for all GMP lentivirus projects, so we offer the flexibility of multiple lentivirus production methods and the expert knowledge to help you decide which process will best meet your individual needs.
Click on the Details link button to get more information!
- Three plasmids, higher yield
- Four plasmids, increased safety
- Related Upstream Technologies
- Related Downstream Technologies
- Related Plasmid Manufacturing